Fabryfacts.com is intended for United States Healthcare Professionals Only. If you are person living with Fabry disease, visit the patient website at www.FabryConnect.com.
close

Dear Fabry Community,
During this challenging time with the global COVID-19 outbreak, it is all the more important we look out for and support one another. The safety and welfare of families affected by rare diseases always has been and continues to be Amicus’ number one priority. Our commitment to the rare disease community will continue and we are only a phone call or email away. For questions or support, we can be reached at patientadvocacy@amicusrx.com or toll-free in the US at 1(866) 9-AMICUS (926-4287). NP-NN-ALL-00020520

The Importance of Genetic Testing

Genetic testing can inform Fabry disease diagnosis and management

Genotype alone does not determine disease progression in Fabry disease—the etiology is complex, and there is great variability in the manifestation and progression of disease.1,2 Even when disease presentation is asymptomatic or mild, the accumulation of disease substrates (including globotriaosylceramide [GL-3] and plasma globotriaosylsphingosine [lyso-Gb3]) can contribute to long-term damage of organs and tissues.3,4 If there is suspicion of Fabry disease, genetic testing is generally recommended.3,5

Genetic testing is the only valid tool to diagnose Fabry disease in heterozygous females because in these women, enzyme activity can appear normal.6

For families affected by Fabry disease, targeted mutational analysis can be used to diagnose at-risk individuals who may not yet exhibit the phenotypic characteristics of the disease.7

Identification of the genetic mutation specific to an individual with Fabry disease may also provide insight into the unique nature of his or her disease, which can lead to a more personalized approach to their disease management.8,9
Recognize the early signs
and symptoms of Fabry disease
Read Now
Review the phenotypic
classifications for Fabry disease
See Table

References:

  1. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-548.
  2. Rozenfeld PA. Fabry disease: treatment and diagnosis. IUBMB Life. 2009;61(11):1043-1050.
  3. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
  4. Namdar M, Gebhard C, Studiger R, et al. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. PLoS One. 2012;7(4):e36373.
  5. Laney DA, Bennett RL, Clarke V, et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2013;22(5):555-564.
  6. Lukas J, Giese A-K, Markoff A, et al. Functional characterisation of alpha-galactosidase A mutations as a basis for a new classification system in Fabry disease. PLoS Genet. 2013;9(8):e1003632.
  7. Yousef Z, Elliott PM, Cecchi F, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J. 2013;34(11):802-808.
  8. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122-138.
  9. Schaefer E, Mehta A, Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr Suppl. 2005;94(447):87-92; discussion 79.